Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy (ASSIST-VLA)

What this Trial Is About

Researchers are evaluating the safety and effectiveness of a gel called 7-940 for women with vaginal atrophy who have recently undergone vaginal laser therapy. This phase 4 study focuses on how well the gel works as an additional treatment to improve symptoms related to vaginal atrophy, such as dryness, tenderness, and discomfort. The study uses both patient and investigator reports to assess clinical outcomes and monitors safety and symptom changes throughout the trial. Participants will apply the 7-940 gel daily following their vaginal laser therapy sessions. The gel is a non-hormonal, non-steroidal product designed to support vaginal mucosal health and speed recovery by promoting a moist healing environment. It is intended as an alternative to estrogen and corticosteroid treatments, aiming to relieve symptoms like itchiness, burning, and painful intercourse, and to improve tissue conditions such as thinning and scarring. During the study, participants will undergo assessments including the Vaginal Health Index Score, the Vulvar Disease Quality of Life questionnaire, and investigator evaluations of vaginal atrophy signs around 30 to 45 days after treatment. Researchers will monitor symptom progression and any complications during this period. Participants will be involved in regular evaluations and provide feedback on their recovery, with the overall study lasting through these follow-up assessments.

ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy